Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
2024

How CMTM6 Causes Resistance to Gemcitabine in Pancreatic Cancer

Sample size: 45 publication 10 minutes Evidence: high

Author Information

Author(s): Zhu Ying‐Qin, Huang Yue, Shi Yin‐Hao, Huang Chen‐Song, Zhao Guang‐Yin, Liu Zhi‐De, Ma Ming‐Jian, Ye Jing‐Yuan, Xu Xiang, Liu Qi, Huang Xi‐Tai, Wang Jie‐Qin, Xu Qiong‐Cong, Yin Xiao‐Yu

Primary Institution: The First Affiliated Hospital of Sun Yat‐sen University

Hypothesis

The study investigates the role of the CMTM6-IGF2BP1-EP300 feedback loop in gemcitabine resistance in pancreatic ductal adenocarcinoma.

Conclusion

The EP300-CMTM6-IGF2BP1 feedback loop enhances gemcitabine resistance in pancreatic cancer, suggesting that targeting this loop may improve treatment outcomes.

Supporting Evidence

  • CMTM6 is upregulated in gemcitabine-resistant pancreatic cancer cells.
  • EP300-mediated H3K27ac modification activates CMTM6 transcription.
  • CMTM6 enhances tumor stemness and contributes to gemcitabine resistance.
  • Combined treatment with EP300 inhibitor inobrodib and gemcitabine shows synergistic effects.
  • High levels of CMTM6 correlate with poor prognosis in pancreatic cancer patients.

Takeaway

This study found that a protein called CMTM6 helps pancreatic cancer cells resist a common chemotherapy drug, gemcitabine, and blocking this protein could help the drug work better.

Methodology

The study used patient-derived xenograft models and RNA sequencing to analyze gene expression related to gemcitabine resistance.

Potential Biases

Potential biases may arise from the selection of cell lines and patient samples.

Limitations

The study primarily focuses on in vitro and preclinical models, which may not fully replicate human responses.

Participant Demographics

Patients with pancreatic ductal adenocarcinoma who had not received prior chemotherapy.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1002/advs.202406714

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication